Evidence map›Paper›PMID 36959312›Full record

ArticleEye (London, England)2023

Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic.

Paulo Eduardo Stanga, Francisco Javier Valentín-Bravo, Sebastian Eduardo Francis Stanga, Ursula Inge Reinstein, Salvador Pastor-Idoate, Susan M Downes

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06572553 (Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
22.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06572553 phase2 / phase3unknown statusnot on this mapstarted 2024, after this paper: background citation

Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

TypeinterventionalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2024 to 2024Enrolled30ConditionsAge-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein OcclusionArmsFaricimab
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. AI-based fluid quantification in neovascular age-related macular degeneration and diabetic macular edema treated with faricimab - a real-life study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  14. Article
  15. Article
  16. Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Paulo Eduardo StangaThe Retina Clinic London, 140 Harley Street, London, W1G 7LB, UK. p.stanga@theretinacliniclondon.com.ORCID 0000-0002-3338-2055
Francisco Javier Valentín-BravoThe Retina Clinic London, 140 Harley Street, London, W1G 7LB, UK.
Sebastian Eduardo Francis StangaThe Retina Clinic London, 140 Harley Street, London, W1G 7LB, UK.
Ursula Inge ReinsteinThe Retina Clinic London, 140 Harley Street, London, W1G 7LB, UK.
Salvador Pastor-IdoateThe Retina Clinic London, 140 Harley Street, London, W1G 7LB, UK.
Susan M DownesThe Retina Clinic London, 140 Harley Street, London, W1G 7LB, UK.
London Clinic · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAssess short-term real-world outcomes in neovascular aged-related macular degeneration (nAMD) treated with novel faricimab.

methodsRetrospective case series of nine patients with nAMD (11 eyes) treated with faricimab between May and November 2022. Treatment-naïve patients and non-naïve patients underwent logMAR best corrected visual acuity (BCVA), optical coherence tomography (OCT) DRI OCT-1 Triton (Topcon Corp, Tokyo, Japan), ultra-widefield (UWF) and fundus autofluorescence (FAF) (California Optomap, Optos plc, Dunfermline, Scotland, UK). Previous treatment intervals, number of intravitreal injections, sub/intra retinal fluid (SRF/IRF), central retinal thickness (CRT) and presence/changes in pigment epithelial detachments (PEDs) were recorded.

resultsMean baseline BCVA and CRT values of patients who switched from other agents were 0.612 ± 0.75 logMAR and 256.16 ± 12.98 µm respectively, with a mean 36-day previous treatment interval. The median number of other previous anti-VEGF intravitreal injections was 8. Mean BCVA at one month significantly improved to 0.387 ± 0.54 logMAR, as well as CRT values which decreased to 245.43 ± 15.34 µm. In the 3 naïve patients, mean baseline BVCA and CRT values were 0.33 ± 0.29 and 874.67 ± 510.86 µm, respectively. At one month follow-up, mean BCVA improved to 0.30 ± 0.29 logMAR and mean CRT was 536.04 ± 36.15 µm. Overall, a significant improvement in BCVA of 0.21 ± 41 logMAR and 238.44 ± 114.9 µm was achieved at one month after the first faricimab intravitreal injection. In addition, a complete resolution of SRF was observed in 6 out of 8 eyes (75%) and of IRF in 2 out of 3 eyes (66.67%), respectively. Drusenoid PED morphology changes were observed in all patients and no drug-related adverse events were observed.

conclusionReal-world outcomes showed improvement in BCVA and anatomic parameters at an early timepoint, demonstrating the efficacy and durability of faricimab in nAMD patients. Larger numbers of patients and longer follow-up are needed to determine whether the loading dose is required in all, what percentage of patients experience an improvement, and whether improvement it is maintained.

Indexed as

Angiogenesis InhibitorsIntravitreal InjectionsTomography, Optical CoherenceVisual AcuityWet Macular DegenerationAgedAged, 80 and overFemaleFluorescein AngiographyHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeVascular Endothelial Growth Factor AAngiogenesis InhibitorsVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID36959312
PMCPMC10564726
OpenAlexW4360611861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.